U.S. markets open in 9 hours 5 minutes

TearLab Corporation (TEAR)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.05790.0000 (0.00%)
At close: 9:35AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0579
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0579 - 0.0579
52 Week Range0.0201 - 0.2150
Avg. Volume32,144
Market Cap1.413M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateMar 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • TearLab Announces Acquisition By Accelmed Partners And Related $25 Million Investment
      PR Newswire

      TearLab Announces Acquisition By Accelmed Partners And Related $25 Million Investment

      TearLab Corporation (OTCQB: TEAR), a leader in Ocular Surface Diagnostics, today announced it has entered into a definitive agreement pursuant to which Accelmed Partners II (AP-II) will acquire TearLab. In connection with the acquisition, AP-II has agreed to an investment of $25 million over two tranches that will occur in conjunction with the company delisting from the "over the counter" OTCQB market and TearLab and its senior secured lender, CR Group, has agreed to restructure the terms of the company's outstanding senior secured indebtedness. Post transaction, TearLab will be a private company and AP-II will be the controlling shareholder. Proceeds from the AP-II investment will be used to pay down a portion of TearLab's existing debt, and fund both organic and inorganic growth opportunities.

    • GlobeNewswire

      TearLab Corporation Confirms Merger Discussions

      Any transaction would be subject to the approval of TearLab’s board of directors and stockholders, as well as other customary conditions contained in a definitive agreement. TearLab cautioned that no agreement has been reached. TearLab also noted that there cannot be any assurance that an agreement will be reached or, if an agreement is reached, that a transaction will be completed.

    • GlobeNewswire

      TearLab Resubmits 510(k) for U.S. FDA Clearance of the TearLab Discovery™ MMP-9 Test

      The submission covers the TearLab Discovery™ Platform and its single-use, disposable Test Card measuring the inflammatory biomarker, matrix metalloproteinase 9 (MMP-9). TearLab Discovery™ will also be capable of performing the Company’s current FDA cleared tear osmolarity test.